03692.HK
Hansoh Pharmaceutical Group Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 36.24
+0.78%Sep 2, 2026, 08:37 UTC
Hansoh Pharmaceutical announced that its self-developed innovative drug HS-20093 for injection has had its marketing authorization application accepted by China's National Medical Products Administration (NMPA) for treating adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based treatment.
Source:Aug 27, 2026, 03:29 UTC
Hansoh Pharmaceutical's stock price rose over 13% on August 27, 2026, reaching a high of HK$36.62, after Morgan Stanley raised its target price to HK$48.
Source:Aug 26, 2026, 09:34 UTC
Hansoh Pharmaceutical declared an interim dividend of 28.5 HK cents per share for H1 2026, up about 23% from 23.16 HK cents in the prior-year period.
Source:Aug 26, 2026, 09:32 UTC
Hansoh Pharmaceutical announced its first-half 2026 results, with revenue of approximately 8.304 billion RMB, up 11.7% year-on-year, and profit of approximately 4.258 billion RMB, up 35.8% year-on-year.
Aug 6, 2026, 13:23 UTC
Hansoh Pharmaceutical announced that its self-developed Class 1 new drug HS-10582 tablet received clinical trial approval from China's National Medical Products Administration for treating adult primary hypercholesterolemia and mixed dyslipidemia.
Source:Jul 28, 2026, 10:17 UTC
GSK and Hansoh Pharmaceutical announced that their experimental drug Ris-Rez met the primary endpoint of progression-free survival in a late-stage trial for bone cancer.
Source:Jul 23, 2026, 03:07 UTC
Chongqing Pharmaceutical Holding and Hansoh Pharmaceutical Group officially launched the Xinfengyi project strategic partnership, covering 9 provinces and municipalities, to integrate resources and deepen collaboration in market access and emerging businesses.
Source:Jul 14, 2026, 10:24 UTC
Avere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.
Jul 10, 2026, 11:37 UTC
Hansoh Pharmaceutical Group announced that its self-developed B7-H3-targeting antibody-drug conjugate HS-20093 met the primary endpoint of overall survival in a Phase III clinical trial for small cell lung cancer, and will soon initiate communication with regulators to prepare for a new drug application in China.